Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051292 | 0.91 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15051659 | 0.86 | BRAF (1.00) | RAF1BRAF | |
| SCHEMBL15052315 | 0.85 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15052274 | 0.85 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15051912 | 0.85 | BRAF (1.00) | RAF1BRAF | |
| SCHEMBL15052371 | 0.84 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15052148 | 0.84 | BRAF (1.00) | RAF1BRAF | |
| SCHEMBL15051367 | 0.84 | BRAF (0.86) | RAF1BRAF | |
| SCHEMBL15051652 | 0.82 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15052153 | 0.82 | RAF1 (1.00) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | claimed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | claimed |
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | CNKSR1, NRAS, HRAS | RAF1 10/4885BRAF 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.